Orally Administered NV-387 Results in Ideal Flat Blood Concentration Profile for Sustained Antiviral Effect [Yahoo! Finance]
NanoViricides, Inc. (NNVC)
NASDAQ:AMEX Investor Relations:
nanoviricides.com/investorinfo.html
Company Research
Source: Yahoo! Finance
SHELTON, CT / ACCESSWIRE / June 11, 2024 / NanoViricides, Inc. (NYSE Amer.: NNVC ) (the "Company"), a clinical-stage global leader in broad-spectrum antiviral nanomedicines, reports that its clinical stage lead nanoviricide broad-spectrum antiviral drug candidate, NV-387, results in an ideal flat blood concentration profile for an extended time period upon oral administration in two different animal models. This unusual but highly desirable, extended flat time profile of blood concentration of orally given NV-387 enables sustained antiviral effect over a long period of time, allowing infrequent dosing regimens. The blood concentration of NV-387 increased to a peak in approximately the first hour, and then remained almost constant for eight hours or longer, thereafter, the concentration declined to reach baseline at about twelve hours; upon oral administration of a first dose of NV-387. This was found to be the case in studies involving two different animal models, namely, rats an
Show less
Read more
Impact Snapshot
Event Time:
NNVC
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
NNVC alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
NNVC alerts
High impacting NanoViricides, Inc. news events
Weekly update
A roundup of the hottest topics
NNVC
News
- NanoViricides Executes an Agreement Encompassing All Antiviral Drug Treatments With Theracour, Including “Trojan Horse” DrugsAccesswire
- MPOX is Emerging as a Global Threat - NanoViricides Investigating MEURI Protocol for Using NV-387 to Treat MPOX [Yahoo! Finance]Yahoo! Finance
- MPOX is Emerging as a Global Threat - NanoViricides Investigating MEURI Protocol for Using NV-387 to Treat MPOXAccesswire
- NanoViricides Continues Its March Towards a Phase II Clinical Trial of NV-387 -?A Potentially Revolutionary First Line Antiviral Therapy for RSV, COVID, and Other Viral InfectionsAccesswire
- NanoViricides Provides an Update on Its Clinical Program and Strategy - NV-387 Could be As Revolutionary as AntibioticsAccesswire
NNVC
Sec Filings
- 9/27/24 - Form 10-K
- 8/9/24 - Form 8-K
- 8/9/24 - Form 424B5
- NNVC's page on the SEC website